image
Healthcare - Biotechnology - NASDAQ - US
$ 1.635
-7.51 %
$ 9.04 M
Market Cap
-0.7
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one APRE stock under the worst case scenario is HIDDEN Compared to the current market price of 1.64 USD, Aprea Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one APRE stock under the base case scenario is HIDDEN Compared to the current market price of 1.64 USD, Aprea Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one APRE stock under the best case scenario is HIDDEN Compared to the current market price of 1.64 USD, Aprea Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart APRE

image
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
1.5 M REVENUE
157.63%
-14.3 M OPERATING INCOME
7.45%
-13 M NET INCOME
9.30%
-13.6 M OPERATING CASH FLOW
-11.32%
-15.5 K INVESTING CASH FLOW
83.37%
14.8 M FINANCING CASH FLOW
188.36%
0 REVENUE
0.00%
-4.09 M OPERATING INCOME
-26.64%
-3.93 M NET INCOME
-35.85%
-3.63 M OPERATING CASH FLOW
-3.43%
0 INVESTING CASH FLOW
0.00%
55.8 K FINANCING CASH FLOW
-58.45%
Balance Sheet Aprea Therapeutics, Inc.
image
Current Assets 23.6 M
Cash & Short-Term Investments 22.8 M
Receivables 0
Other Current Assets 726 K
Non-Current Assets 403 K
Long-Term Investments 0
PP&E 81.5 K
Other Non-Current Assets 322 K
95.29 %3.03 %Total Assets$24.0m
Current Liabilities 3.36 M
Accounts Payable 1.35 M
Short-Term Debt 0
Other Current Liabilities 2.01 M
Non-Current Liabilities 1.31 M
Long-Term Debt 0
Other Non-Current Liabilities 1.31 M
28.94 %42.99 %28.06 %Total Liabilities$4.7m
EFFICIENCY
Earnings Waterfall Aprea Therapeutics, Inc.
image
Revenue 1.5 M
Cost Of Revenue 22.3 K
Gross Profit 1.48 M
Operating Expenses 15.8 M
Operating Income -14.3 M
Other Expenses -1.36 M
Net Income -13 M
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)2m(22k)1m(16m)(14m)1m(13m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
98.51% GROSS MARGIN
98.51%
-953.00% OPERATING MARGIN
-953.00%
-862.43% NET MARGIN
-862.43%
-67.12% ROE
-67.12%
-54.04% ROA
-54.04%
-69.45% ROIC
-69.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Aprea Therapeutics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -13 M
Depreciation & Amortization 22.3 K
Capital Expenditures -15.5 K
Stock-Based Compensation 489 K
Change in Working Capital -1.06 M
Others -796 K
Free Cash Flow -13.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Aprea Therapeutics, Inc.
image
APRE has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Aprea Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
29.6 K USD 1
9-12 MONTHS
0 USD 0
Bought
10.1 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
166 K USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial globenewswire.com - 1 month ago
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition globenewswire.com - 3 months ago
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025 $22.8 million in cash and cash equivalents as of December 31, 2024 DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. globenewswire.com - 3 months ago
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Under the agreement, Aprea will supply its proprietary WEE1 kinase inhibitor, APR-1051, to support preclinical research aimed at exploring its potential in treating HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) expressing genomic markers of replication stress. globenewswire.com - 3 months ago
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio. globenewswire.com - 4 months ago
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle globenewswire.com - 6 months ago
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. zacks.com - 7 months ago
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.86 per share a year ago. zacks.com - 7 months ago
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the U.S. globenewswire.com - 8 months ago
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024. globenewswire.com - 8 months ago
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that four abstracts have been accepted for poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, October 23 - 25, 2024. Details on the posters are below. globenewswire.com - 8 months ago
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor. globenewswire.com - 8 months ago
8. Profile Summary

Aprea Therapeutics, Inc. APRE

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 9.04 M
Dividend Yield 0.00%
Description Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Contact 535 Boylston St., Boston, MA, 02116 https://atrinpharma.com
IPO Date Oct. 3, 2019
Employees 8
Officers Mr. Brian Wiley Senior Vice President of Corporate Development & Strategy Ms. Andrea Epstein Controller Dr. Oren Gilad Ph.D. Co-Founder, Chief Executive Officer, President & Director Dr. Lars B. Abrahmsen Ph.D. Senior Vice President & Chief Scientific Officer Mr. Ze'ev Weiss B.Sc., C.P.A. Chief Business Advisor Dr. Michel Afargan Ph.D. Head of Pharmacology Development Mr. John P. Hamill CPA Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Secretary